新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 癌症研究 » CCDT:肝细胞癌精准治疗目标

CCDT:肝细胞癌精准治疗目标

来源:生物谷 2016-03-11 10:14

2016年3月11日讯/生物谷BIOON/了解肝细胞瘤相关的分子遗传学, 结合分子肿瘤分析开发靶向疗法可以帮助治疗肝细胞癌(HCC)患者。

在最近发表的一篇文章中, Nelson Yee 博士和Eric Marks博士提供了一种更新的异常基因和肝细胞癌的致癌作用机制,并讨论了靶向治疗这种疾病患者的临床调查。

多步骤形成的肝细胞癌通常开始于慢性炎症,之后逐渐转变成浸润性癌。这些事件的发生与分子异常和染色体改变有关。生长因子和受体的活性的异常表达,相关的信号通路在肝细胞癌的发展和恶化中受影响,他们被利用作为治疗靶点。在这些靶向制剂中,多种激酶抑制剂索拉非尼已经成为标准的治疗晚期肝癌的方法,但其疗效是有限的。

靶向制剂抑制受体酪氨酸激酶及其下游信号介质、血管生成和免疫调制剂已经被开发并进行了临床调查。继续研究需要集中利用分子概念来指导选择肝癌的靶向治疗,希望找到治疗这种恶性疾病的最佳方法。

肝细胞癌是一种高度致命的恶性肿瘤, 迫切需要治疗改善疾病反应和可耐受毒性。本文提供了一个当前的和全面的肝细胞癌的分子遗传学和靶向治疗的观点。这为医学研究人员,临床调查、临床医生和患者肝细胞癌提供了有效信息。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!点击 获取授权 。更多资讯请下载生物谷APP.

Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma

Eric I. Marks and Nelson S. Yee

PHepatocellular carcinoma (HCC) is a highly lethal disease, therefore effective and tolerable treatment is urgently needed. In this article, we provide an updated review of the genetic abnormalities and mechanisms that drive carcinogenesis of HCC, and discuss the targeted therapeutics that are being investigated in HCC. Hepatocellular carcinogenesis typically begins with chronic inflammation of hepatocytes that progressively transform into invasive carcinoma. These events are associated with molecular abnormalities and chromosomal alterations. Multiple analyses of HCC have revealed aberrant expression or activity of growth factors and receptors, and the associated signaling pathways. These molecular alterations are implicated in the development and progression of HCC, and they have been exploited as targets for therapy. Targeted agents that inhibit receptor tyrosine kinases and their downstream signal mediators, angiogenesis, and immunomodulators have been developed and clinically investigated. Among these targeted agents, the multi-kinase inhibitor sorafenib has become the standard treatment for advanced HCC, though its therapeutic benefit is limited. Continued research is essential for improving treatment response and minimizing toxicity for patients with HCC. Future investigation will need to focus on utilizing patterns of gene expression to classify HCC into groups that display similar prognosis and treatment sensitivity, and combining targeted therapeutics with conventional chemotherapy that produce enhanced anti-tumor effect. By integration of tumor profiling and targeted therapeutics in HCC, we hope to advance towards the goal of precision treatment for patients with this malignant disease.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库